- Home
- NTZ vs TVRD Comparison
NTZ vs TVRD Comparison
Compare NTZ & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTZ | TVRD |
|---|---|---|
| Founded | 1959 | 2017 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 36.8M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | NTZ | TVRD |
|---|---|---|
| Price | $3.12 | $3.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 6.1K | ★ 50.8K |
| Earning Date | 04-13-2023 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $2.75 |
| 52 Week High | $5.00 | $43.65 |
Technical Indicators
Market Signals| Indicator | NTZ | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 43.46 |
| Support Level | $3.07 | $2.75 |
| Resistance Level | $3.20 | $4.45 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 86.44 | 53.15 |
Price Performance
Historical ComparisonAbout NTZ Natuzzi S.p.A.
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.